tbuckley/cabot-search huggingface dataset:
Integrating primary care and cancer care in survivorship: A collaborative approach.
Authors: Jonathan Sussman, Mary L McBride, Jeffrey Sisler, Grace Kim, Laura Game, Emmanuel Ozokwelu, Joel Roger Gingerich, Stefanie De Rossi, Maria Grant
Journal: Journal of Clinical Oncology (2016)

103 Background: Primary care providers (PCPs) have an important role in the provision of survivorship care. While there is evidence to support the feasibility and safety of PCP-led survivorship care, there are gaps in knowledge about how to best integrate providers to support transitions, enhance quality of care, increase system efficiencies, and improve patient and provider satisfaction. Methods: A pan-Canadian study comprised of three projects has been initiated to address three key aspects of care integration, based on a previously described system performance framework. Functional integration will be studied through the evaluation of electronic survivorship care plans using a prospective cohort of breast and colorectal cancer patients with pre and post measures of knowledge, care coordination, and satisfaction. Vertical integration will be evaluated through a series of descriptive case studies to document structures and processes that are currently in place to support PCP re-referral to regional cancer centres. Clinical integration will be studied through the development and evaluation of an interspecialty survivorship training curriculum for oncology and family medicine trainees. Results: Functional integration: Development of an electronic platform for care plan outputs is complete. Two sites in Ontario (ON) and one in British Columbia (BC) have been selected to study the impact on 200 patients and their providers. Vertical integration: Using a study-specific interview guide, 48 semi-structured key informant interviews have been successfully conducted in ON; 15 interviews are planned for Manitoba (MB) and 15 for BC. Clinical Integration: a National Advisory Committee was established and needs assessments were performed with postgraduate program directors, cancer survivors, and trainees using online surveys and focus groups. A blended learning curriculum is being piloted in MB, ON, and BC in 2015. Conclusions: Integrating primary care and cancer care in survivorship requires a collaborative approach that begins in residency, supports PCPs with clear mechanisms for re-entry, and optimizes communication. This study will inform approaches to enhancing provider integration and survivorship care.
TKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation
Authors: L. Zdrazilova Dubska, L. Fedorova, K. Pilatova, P. Mudry, E. Hlavackova, E. Matoulkova, L. Flajsarova, R. Demlova, D. Valik, J. Sterba
Journal: Annals of Oncology (2016)
Early-life Lactobacillus rhamnosus GG Supplementation of High-risk for Asthma Infants Reprograms Gut Microbiota Development and promotes regulatory T-cells
Authors: Juliana Durack, Nikole E. Kimes, Din Lin, Michelle McKean, Marcus Rauch, Michael D. Cabana, S.V. Lynch
Journal: Journal of Allergy and Clinical Immunology (2017)
Patient utilization of supportive care services identified through the Athena Breast Health Questionnaire System.
Authors: Emily Claire Wong, Celia Kaplan, Dianne Shumay, Yan Leykin, Laura Van't Veer, Allison Stover-Fiscalini, Laura Esserman, Michelle Melisko
Journal: Journal of Clinical Oncology (2016)

226 Background: Psychological wellbeing and lifestyle changes are important factors in long-term health of cancer survivors. As part of the Athena Breast Health Network, the UCSF Breast Care Center (BCC) incorporated an electronic health questionnaire system (HQS) that collects patient-reported data on physical and psychological symptoms, medical conditions, family history, and lifestyle to identify patients’ supportive care needs. Methods: Through a semi-automated process, patients whose HQS responses meet pre-established thresholds are referred to Psycho-Oncology, social work, genetic counseling, and Onco-Fertility. Referrals generated within the HQS are signed and routed by clinicians at the time of a BCC visit. When patients decline appointments with these services, staff members document reasons within the electronic medical record (EMR). A retrospective chart review identified patients who did not receive supportive care services to which they were referred and a qualitative analysis was performed. Results: From 7/1/14-12/31/14, 525 patients completed an HQS and agreed to have their data used for research. The table summarizes referral information. 45 patients referred to Psycho-Oncology did not complete an appointment. Of these, ten did not respond to phone contact to schedule visits. 35 were reached, but declined an appointment. 25 (71.4%) were not ready to make an appointment; 5 (14.3%) cited distance as a primary barrier; 3 (8.6%) were satisfied with the psychological services they were receiving elsewhere; and 2 (5.7%) did not have insurance coverage. Reasons women disregarded referrals for genetic counseling and fertility are being evaluated. Conclusions: HQS can assist in identifying patient supportive care needs, but despite automation of referrals, many patients do not follow through to use supportive care and clinical resources. Timing and resource accessibility may be key. Through analysis of reasons for non-utilization, we hope to better tailor the delivery of supportive care services, when indicated, to better serve patient needs. [Table: see text]
Characterization of the length of the deletions of the long arm of chromosome 9 in Philadelphia-positive CML using microarray-based comparative genomic hybridization.
Authors: Joelle Tchinda
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

142 

The diagnostic hallmark of chronic myelogeneous leukemia (CML), the Philadelphia (Ph) translocation, has been proven to be most important for diagnosis and monitoring of the disease. The Ph-translocation leads to fusion of the ABL gene located on 9q34 to the BCR gene on 22q11. Its partial or complete disappearance is correlated to the clinical outcome. Fluorescence in situ hybridization (FISH) has been proven to be a helpful technique in diagnosis and monitoring of BCR-ABL gene fusion. A minority of of patients with CML had large deletions adjacent to the translocation breakpoint on the derivative chromosome 9, on the additional partner chromosome in variant translocations, or on both. Several studies have shown those cases to have a poorer outcome than cases with only the Ph-translocation. To assess the extent of the deletion of chromosome 9 and 22 sequences, we performed microarray-based comparative genomic hybridization (array-CGH) on a platform with 6935 clones on five Ph-positive cases of CML. The deletion on 9q have been detected beforehand with a BCR-ABL FISH probe (fluorescence in situ hybridization) in bone marrow samples of these patients (Table 1). The lengths of the deletions vary between 747.035 bps and 3.587.395 bps (Table 1). A trisomy 21 and additional Ph-chromosome were confirmed. New submicroscopic gains and losses were also detected. We here present the first study on array CGH used to characterize the lengths of the deletion of chromosome 9 and 22 sequences in Ph positive CML. The length of the deletion seems not to influence the clinical course of the disease within this subgroup of patients. These data represent just a tendency, since only five cases have been investigated in this pilot study. A study with a larger number of cases is needed to confirm this assumption. Table 1. Correlation between FISH patterns used to detect the deletions and lengths of the deletions on 9q and 22q detected with array CGH *Patterns are observed with the LSI BCR/ABL Dual Color Dual Fusion (D-FISH) probe; f: fusion (#Ph); r: red (#9); g: green (#22)



![Figure][1]  [1]: pending:yes
Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma
Authors: Zhishuo Ou, Lan V Pham, Liang Zhang, Archito T. Tamayo, John Lee, Kejie Zhang, Jacqueline Wang, James Phan, Changping Li, Luhong Sun, Richard J. Ford, Michael Wang
Journal: Blood (2011)
Intravenous Fentanyl and Potential Mortality
Authors: Xiulu Ruan, Hong Wu, Nalini Sehgal
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC).
Authors: J. Liu, K. S. Albain, S. Chan, A. D. Seidman, D. Tai, Y. Wang, L. Zhao
Journal: Journal of Clinical Oncology (2011)

2552 Background: Estimation of overall survival (OS) in the evaluation of new treatment regimens for MBC is limited by the prolonged time for pt follow-up and by the potential impact of subsequent therapies. Identification of a surrogate parameter to predict OS could help in the design of future trials. Previous analyses in pts with non-small-cell lung cancer have suggested that both response rate (RR; pts with CR or PR) and disease control rate (DCR; pts with CR, PR, or SD) measured at 8 weeks after treatment initiation may predict OS (Lara et al, J Clin Oncol, 2008). We evaluated data from 3 first-line phase III MBC trials (Albain et al, J Clin Oncol, 2008; Chan et al, J Clin Oncol, 2009; and Seidman et al, Ann Oncol, 2010) to assess any possible association of RR or DCR at 8 weeks of treatment with OS. Methods: Landmark analyses using Cox proportional hazard models were performed separately with data sets from 3 previously published phase III trials in which pts with anthracycline‐pretreated MBC were administered various chemotherapy regimens. Efficacy evaluable pts, who received tumor assessments at 8 weeks and up to 22 weeks after the initiation of therapy, were assessed. Hazard ratios (HR) were used to assess the associations between response parameters and OS. Results: RR at about 8 weeks was significantly associated with OS in the Albain et al trial (HR=0.63, 95% CI: 0.48-0.82, P=0.0005), but was not associated with OS in the Chan et al trial (HR=0.82, 95% CI: 0.59-1.13, P=0.2255) or in the Seidman et al trial (HR=0.76, 95% CI: 0.57-1.02, P=0.0637). DCR at approximately 8 weeks was significantly associated with OS in all three trials: Albain et al, HR=0.55, 95% CI: 0.41-0.75, P=0.0001, N=277; Chan et al, HR=0.43, 95% CI: 0.27-0.70, P=0.0007, N=193; Seidman et al, HR=0.34, 95% CI: 0.22-0.51, P <0.0001, N=275. At later time points, DCR showed consistently stronger association with OS compared to RR. Conclusions: In landmark analyses of 3 MBC trials, the association of OS with early DCR was greater than with RR. If prospectively validated, 8-week DCR may provide an early look to assess value of systemic treatment of MBC.
Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM).
Authors: Noopur Raje, Shaji Kumar, Teru Hideshima, Kenji Ishitsuka, Aldo Roccaro, Hiroshi Yasui, Makoto Hamasaki, Norihiko Shiraisi, Nikhil C. Munshi, Howard Elford, Kenneth C. Anderson
Journal: Blood (2004)
Opioid Receptors Stimulate Angiogenesis, Lymphangiogenesis and Neurogenesis in Ischemic Wounds in Sickle Mice.
Authors: Kalpna Gupta, Yunfang Li, Nicholas A. Mason, Tou S. Vang, Brett K. Levay-Young, Marna E. Erickson, Robert P. Hebbel
Journal: Blood (2006)
Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users
Authors: Lion Shahab, Maciej L. Goniewicz, Benjamin C. Blount, Jamie Brown, Ann McNeill, K. Udeni Alwis, June Feng, Lanqing Wang, Robert West
Journal: Annals of Internal Medicine (2017)

Given the rapid increase in the popularity of e-cigarettes and the paucity of associated longitudinal health-related data, the need to assess the potential risks of long-term use is essential.
Pre- and postoperative plasma concentrations of five novel candidate biomarker proteins in patients with high- and low-grade gliomas.
Authors: Matthias Holdhoff, Susannah G. Yovino, William J. Savage, Pratima Dulloor, Stuart A. Grossman, Allen Everett
Journal: Journal of Clinical Oncology (2012)

21 Background: Current imaging techniques are unable to accurately measure tumor burden in gliomas, because they rely on blood-brain barrier (BBB) permeability that is altered following surgery, radiation, steroids, and antiangiogenic therapies. This often leads to misinterpretation of disease status and incorrect clinical decisions. The development of tumor-specific blood-based markers for gliomas is therefore critically important. This study evaluates the detectability of five novel protein biomarker candidates in the plasma of patients with gliomas: neurogranin, ICAM-5, beta-synuclein, brain-derived neurotrophic factor (BDNF), and glial fibrillary acidic protein (GFAP). These biomarker candidates were chosen because of their specificity for brain tissue. Methods: Pre- and postoperative plasma samples were obtained from patients with newly diagnosed gliomas with IRB approval. Plasma concentrations were measured in duplicates using an electrochemiluminescent immunoassay with a lower limit of quantification of &gt;0.04ng/mL (GFAP) and &gt;0.02 ng/mL (other markers). Results: Plasma levels were detectable for all 5 tested markers at baseline and postoperatively. Baseline levels were highly variable and postoperative GFAP levels were much higher than preoperative levels likely related to brain injury (see table). Conclusions: Five potentially useful protein markers have been identified in the plasma of patients with gliomas. Further studies are underway to assess the specificity of each marker and its ability to detect dynamic changes in tumor burden. [Table: see text]
GATA3 Silencing Defines a Distinct Subset of ETP-ALL.
Authors: Lars Fransecky, Martin Neumann, Sandra Heesch, Marco Seehawer, Cornelia Schlee, Liliana H. Mochmann, Stefan Schwartz, Nicola Goekbuget, Dieter Hoelzer, Claudia D Baldus
Journal: Blood (2012)
Fighting TB requires empowered patients
Authors: Deepti Chavan
Journal: BMJ (2017)

Fighting TB requires empowered patientsIn this article from India, Deepti Chavan describes the differences in health outcomes when patients are able to access the information they need Deepti ChavanI was 16 when I first started coughing.It was in the middle of school exams.After months of coughing non-stop, I had a chest x ray and it was confirmed."You have TB," my general practitioner said.These three words changed my life.I didn't know anything about this disease.I was about to start university.Everything changed.From a young person filled with hope I became an anxious patient.
Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation
Authors: Maarten L. Zandvliet, J.H. Frederik Falkenburg, Michel G.D. Kester, Arnoud H. de Ru, Peter A. van Veelen, Roelof Willemze, Henk-Jan Guchelaar, Pauline Meij
Journal: Blood (2008)
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.
Authors: Asher A. Chanan-Khan, Kena C. Miller, Dawn DePaolo, Swaminathan Padmanabhan, Amy Whitworth, Sikander Ailawadhi, Kelvin Lee, Myron S. Czuczman
Journal: Blood (2007)
Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera.
Authors: Paola Guglielmelli, Lorenzo Tozzi, Vanessa Ponziani, Elisa Bianchi, Ilaria Iacobucci, Betty Giusti, Luciana Rossi, Giovanni Martinelli, Rossella Manfredini, Alberto Bosi, Alessandro M. Vannucchi
Journal: Blood (2009)
Therapeutic effect of Songlingxuemaikang capsule in elderly patients with stable angina
Authors: Jia Zhi-mei, Jiang Wen-yan, Jia Zhi-jun
Journal: BMJ (2011)

Eighty two patients aged 60 or over with stable angina pectoris were randomized to control group ( n = 42, receiving conventional western medicine) and treatment group ( n = 40, receiving 1.5 g Songlingxuemaikang capsules three times a day in addition to western medicine) .The treatment was lasted for 12 weeks, angina classification of CCS, hs-CRP, blood pressure levels and SF-36 (36-item short form)of the patients were evaluated before and after the treatment.The degrees of angina pectoris in angina classification of CCS, hs-CRP and blood pressure levels decreased, and the quality of life was improved in both groups; but more markedly in treatment group than those in control group (P ＜ 0.05 ).Songlingxuemaikang capsule combined with conventional western medicine can effectively relieve the symptoms of ischemic chest pain in elderly patients with stable angina pectoris, which is associated with blood pressure reduction and life quality improvement.

Key words: 
Angina pectoris;  Drugs, chinese hebal
Tissue array analysis in patients with renal cancer.
Authors: Maria C Areses Manrique, Urbano Anido, Ihab Abdulkader, Luis Leon
Journal: Journal of Clinical Oncology (2012)

450 Background: Development and progression of kidney cancer is the result of an imbalance in signals promoting and inhibiting cellular proliferation and apoptosis. The aim of this study is to analize the expression of some molecular regulators and correlate them with clinical outcome in renal carcinoma, in order to establish common prognostic biomarkers. Methods: Tissue sample was obtained from nephrectomized patients in our center between 1998 and 2003. Biopsies were taken from 150 patients; a tissue array was done to analyze immunoexpression of proteins related to proliferation, cell cycle control and angiongenesis: p53, Ki 67, VEGF, VEGFR1, VEGFR2, HIF1, HIF2, cyclin D1, cyclin D3, cyclin B1, cyclin A, bcl2, p63, COX2, p16, p27, p21, EGFR, PDGF, PTEN, CAIX, BRAF, Akt and P13K. Subsequently the results were correlated with clinical variables (age, hypertension, smoking), pathological (tumor size, stage, Fuhrman grade) and time to progression and overall survival. Results: 92.3% of patients underwent nephrectomy, 11% associated with lymphadenectomy. Histology: 66.6% clear cell his, 14.1% papillary, chromophobe 6.4% and 15% miscellaneous. Stage I 49.4%; II 17.9%; 14.7% III; IV 14.1%; 3.8% unknown. Of the 150 patients analyzed, 23% had a second tumor. Median time to progression was 90.5 months (95% CI 81.7 to 114.3). The median survival has not yet been reached. Results of tissue array analysis wil be presented in the meeting. Conclusions: Patients in this serie have a good prognosis, since most tumors are stage I and II. We will present data on the expression of factors related to proliferation, cell cycle control and angiogenesis.
An Evolutionarily Conserved Role for Polydom/Svep1 During Lymphatic Vessel Formation
Authors: Terhi Karpanen, Yvonne Padberg, Serge A. van de Pavert, Cathrin Dierkes, Nanami Morooka, Josi Peterson-Maduro, Glenn van de Hoek, Max Adrian, Naoki Mochizuki, Kiyotoshi Sekiguchi, Friedemann Kiefer, Dörte Schulte, Stefan Schulte-Merker
Journal: Circulation Research (2017)

Lymphatic vessel formation and function constitutes a physiologically and pathophysiologically important process, but its genetic control is not well understood.Here, we identify the secreted Polydom/Svep1 protein as essential for the formation of the lymphatic vasculature. We analyzed mutants in mice and zebrafish to gain insight into the role of Polydom/Svep1 in the lymphangiogenic process.Phenotypic analysis of zebrafish polydom/svep1 mutants showed a decrease in venous and lymphovenous sprouting, which leads to an increased number of intersegmental arteries. A reduced number of primordial lymphatic cells populated the horizontal myoseptum region but failed to migrate dorsally or ventrally, resulting in severe reduction of the lymphatic trunk vasculature. Corresponding mutants in the mouse Polydom/Svep1 gene showed normal egression of Prox-1+ cells from the cardinal vein at E10.5, but at E12.5, the tight association between the cardinal vein and lymphatic endothelial cells at the first lymphovenous contact site was abnormal. Furthermore, mesenteric lymphatic structures at E18.5 failed to undergo remodeling events in mutants and lacked lymphatic valves. In both fish and mouse embryos, the expression of the gene suggests a nonendothelial and noncell autonomous mechanism.Our data identify zebrafish and mouse Polydom/Svep1 as essential extracellular factors for lymphangiogenesis. Expression of the respective genes by mesenchymal cells in intimate proximity with venous and lymphatic endothelial cells is required for sprouting and migratory events in zebrafish and for remodeling events of the lymphatic intraluminal valves in mouse embryos.
Usefulness of Positron Emission Tomography Using 18F-FDG Performed At Diagnosis and During Initial Chemotherapy for Imaging Primary Central Nervous System Lymphoma: A 24 Immunocompetent patient's Study.
Authors: Herve Ghesquieres, Céline Ferlay, Bertrand Richioud, Vanina Isnardi, Emmanuelle Nicolas-Virlizier, Izabela-Irina Domnisoru, Philippe Rey, François Ducray, Jérome Honnorat, Emmanuel Jouanneau, Marie Pierre Sunyach, Pierre Biron, Catherine Sebban, Jean-Yves Blay, Sébastien Cimarelli
Journal: Blood (2011)
A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
Authors: Leslie A. Andritsos, William Blum, Rebecca B. Klisovic, Sumithira Vasu, Sam Penza, Jodi Lee, Guido Marcucci, John C. Byrd, Steven M. Devine
Journal: Blood (2014)
Natural Evolution of NSAID-Induced Urticaria/Angioedema over a 10-Year Follow-up
Authors: Inmaculada DoÑa, Maria Salas, Esther Barrionuevo, Oliver Muñoz Daga, Maria Isabel Sánchez-Rivas, Maria Auxiliadora Guerrero, Arturo Ruiz San Francisco, Paloma Campo, Maria J. Torres
Journal: Journal of Allergy and Clinical Immunology (2017)